Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 3,917 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Open Angle Glaucoma
Interventions: NCX 470, Placebo; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Vitamin D Deficiency, Insulin Resistance, Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension
Interventions: Vitamin D3, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 25 Years to 80 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypertension
Interventions: Health Literacy-Focused High Blood Pressure Intervention; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 60 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Ellicott City, Maryland

Conditions: Hypertension, Essential (Primary) Hypertension
Interventions: Mindfulness in Motion; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pulmonary Hypertension
Interventions: No Intervention; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Heart Failure
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Pulmonary Arterial Hypertension
Interventions: Ambrisentan; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: New Orleans, Louisiana • Charleston, South Carolina

Conditions: Pulmonary Embolism, Pulmonary Hypertension, Thromboembolism, Right Ventricular Dysfunction
Interventions: Alteplase, EKOS; Drug · Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 89 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Bay Shore, New York • Queens, New York

Conditions: Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
Interventions: Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging; Drug · Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Hypertension, Portal
Interventions: SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles), SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 6 Years to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Venous Insufficiency
Interventions: Physical Conditioning; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: East Orange, New Jersey

Conditions: Young Adults, Hypertension, Post-Exercise Hypotension, Circadian Rhythm
Interventions: Exercise; Behavioral
Lead sponsor: Freda Patterson; Other
Eligibility: 18 Years to 39 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Hypertension
Interventions: BP Activate Letter, Control Letter; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypertension, High Blood Pressure
Interventions: LINKED-BP Program; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Bowie, Maryland + 11 more

Conditions: Hypertension,Essential, Adherence, Medication, Quality of Life
Interventions: Coaching application, WebMD, Home-based blood pressure monitoring; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hyperkalemia
Interventions: Patiromer, Placebos; Drug
Lead sponsor: Vifor Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 133
States / cities: Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more

Conditions: Pulmonary Arterial Hypertension
Interventions: macitentan (ACT-064992), placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 33
States / cities: Birmingham, Alabama • Pheonix, Arizona • Los Angeles, California + 28 more

Conditions: Chronic Kidney Disease, Hypertension
Interventions: Protocolized, pharmacist-delivered CKD Action Plan; Other
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Chronic Kidney Diseases, Hypertension, Diabetes
Interventions: CKD enhanced clinical decision support; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 6,295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bloomington, Minnesota

Conditions: Pulmonary Arterial Hypertension
Interventions: Sorafenib; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depression
Interventions: TEAM-Red, Waitlist; Behavioral · Other
Lead sponsor: Jennifer B. Levin; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Kidney Disease
Interventions: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 44
States / cities: Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure
Interventions: ALZ-1101, Latanoprost; Drug
Lead sponsor: Alleanza Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Morrow, Georgia

Conditions: Hypertension
Interventions: mGlide; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 85 Years
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

Vitamin D, Insulin Resistance, and Cardiovascular Disease

Health Literacy-Focused Program to Improve Blood Pressure Control in Korean Americans

Evaluating the Effects of a Mindfulness Intervention on Health Outcomes in Individuals With Hypertension

Fractal Analysis of the Pulmonary Arterial Tree in Pulmonary Hypertension

"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure

Crossover Study From Macitentan or Bosentan Over to Ambrisentan

Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE

Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

SHAPE of Portal Hypertension in Children

Physical Conditioning in Management of Chronic Venous Insufficiency

Examining the Circadian Timing Effects of the Hypotensive Response to Exercise

UCSF BP Activate Letter Study

Home Blood Pressure Telemonitoring LINKED With Community Health Workers to Improve Blood Pressure

Mobile Health Program for Rural Hypertension

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

Early Identification and Action in CKD

Chronic Kidney Disease Clinical Decision Support

Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)

TEAM-Red, a Remotely Delivered Self-management Program for Depressed Black Women at Risk for Hypertension

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost

mGlide RCT: A Clinical Glide Path To Close the Guideline-to-Practice Gap In HTN Management